$RVV $RVVTF - THE PSYCHEDELIC MARKET The story of psychedelics as therapeutic treatments is now unfolding across the world. There is a lot of promising research into a wide variety of problematic neurological and psychological conditions that have resisted more traditional treatments to date. It’s a potentially explosive industry in its infancy. “Psychedelics are a boom business.”
Recreational: $ 8-19.2B calculated from cannabis market and comparable usage prevalence as well as demand size economics.
Medical: $ 373B + calculated from the main markets addressable by psychedelic therapeutics (neurogenics market): mental health drugs, therapy spending, neurodegeneration drugs and cognitive enhancement.
Revive Therapeutics Ltd. is a life sciences company focused on the research and development of therapeutics for rare disorders and infectious diseases. With its recent acquisition of Psilocin Pharma Corp., Revive will advance Psilocybin-based therapeutics in various diseases and disorders and will prioritize development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations.
Revive Therapeutics Announces Research Partnership Agreement with the University of Wisconsin-Madison to Evaluate Novel Formulations and Drug Delivery Technology Focused on Psilocybin-Based Pharmaceuticals.
The Company is also exploring the use of Bucillamine for the potential treatment of infectious diseases, including COVID-19.